The DKK1 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, with targeted disruption of the DKK1 gene. This product provides a heterogeneous mixture of gene-edited cells, enabling studies of DKK1 loss-of-function within a polyclonal background. The CRISPR/Cas9-mediated gene disruption ensures stable ablation of DKK1 expression, creating a robust model for investigating Wnt pathway regulation and its roles in cancer biology.
The A2780 cell line was established from an untreated ovarian endometrioid adenocarcinoma patient and serves as a widely used epithelial ovarian cancer model, particularly sensitive to platinum-based chemotherapy. This cell line retains key characteristics of ovarian carcinoma, making it a valuable platform for studying tumorigenesis, drug response, and signaling networks in a clinically relevant context.
DKK1 is a secreted antagonist of the Wnt/??-catenin signaling pathway that functions by binding to LRP5/6 co-receptors and Kremen proteins, triggering internalization and degradation of LRP5/6 and thereby preventing Wnt-Frizzled interaction. This blockade inhibits ??-catenin stabilization, leading to reduced nuclear accumulation of ??-catenin and suppression of TCF/LEF-mediated transcription of Wnt target genes such as AXIN2, MYC, and CCND1. Upstream regulators including Wnt ligands (Wnt3a, Wnt1), the ??-catenin/TCF complex, p53, and glucocorticoids modulate DKK1 expression, while downstream effects involve diminished transcription of pro-proliferative and pro-invasive factors.
In the context of A2780 ovarian carcinoma cells, DKK1 knockout disrupts an endogenous negative feedback loop of the Wnt pathway, potentially altering cell proliferation, apoptosis, and chemosensitivity. Given the reported involvement of Wnt signaling in platinum resistance and tumor microenvironment interactions, this polyclonal knockout model allows researchers to explore how loss of DKK1 impacts ovarian cancer cell behavior, including migration, invasion, and response to chemotherapeutic agents.
This knockout model is suited for a wide range of applications, including studying Wnt pathway inhibition in ovarian cancer, investigating chemoresistance mechanisms, screening Wnt pathway modulators, and evaluating tumor microenvironment interactions. Representative assays include Western blotting for ??-catenin and phospho-LRP6, RT-qPCR for AXIN2 and MYC, TOP/FOP luciferase reporter assays, immunofluorescence for ??-catenin localization, and migration/invasion assays. For further technical information or to request a sample, please contact Ascent Research.
